MACROD2 expression predicts response to 5-FU-based chemotherapy in stage III colon cancer

Evert van den Broek, Sjoerd H. den Uil, Veerle M. H. Coupé, Pien M. Delis-van Diemen, Anne S. Bolijn, Herman Bril, Hein B. A. C. Stockmann, Nicole C. T. van Grieken, Gerrit A. Meijer, Remond J. A. Fijneman

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Colorectal cancer (CRC) is caused by genetic aberrations. MACROD2 is commonly involved in somatic focal DNA copy number losses, in more than onethird of CRCs. In this study, we aimed to investigate the association of MACROD2 protein expression with clinical outcome in stage II and stage III colon cancer. Methods: Tissue microarrays (TMA) containing formalin-fixed paraffinembedded tissue cores from 386 clinically well-annotated primary stage II and III colon cancers were stained by immunohistochemistry and evaluated for MACROD2 protein expression. Disease-free survival (DFS) analysis was performed to estimate association with clinical outcome. Results: Loss of nuclear MACROD2 protein expression in epithelial neoplastic cells of stage III microsatellite stable (MSS) colon cancers was associated with poor DFS within the subgroup of 59 patients who received 5-fluorouracil (5-FU)-based adjuvant chemotherapy (p=0.005; HR=3.8, 95% CI 1.4-10.0). Conclusion: These data indicate that low nuclear expression of MACROD2 is associated with poor prognosis of patients with stage III MSS primary colon cancer who were treated with 5-FU-based adjuvant chemotherapy.
Original languageEnglish
Pages (from-to)29445-29452
JournalOncotarget
Volume9
Issue number50
DOIs
Publication statusPublished - 2018

Cite this